pharmaceuticals - Page 3

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

The more disruptive the market is, the more we look for companies that are not affected by the daily sturm and drang of the news cycle because they have supply ...
Read Full Story »

Why the FDA Is a Little Slow on This Jet Lag Study

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares dropped early to begin the week after the firm announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug ...
Read Full Story »

Huge Plaque Psoriasis Breakthrough at Eli Lilly

Eli Lilly and Co. (NYSE: LLY) shares made a handy gain on Tuesday after the firm announced results from its late-stage study for the treatment of moderate to severe plaque ...
Read Full Story »

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Is GlycoMimetics’ Sickle Cell Study Done For?

GlycoMimetics Inc. (NASDAQ: GLYC) shares were crushed on Monday after the firm announced late-stage results from its sickle cell disease (SCD) trial in conjunction with Pfizer Inc. (NYSE: PFE). SCD ...
Read Full Story »

Why Keytruda Made All the Difference in Merck’s Q2

Merck & Co. Inc. (NYSE: MRK) released its second-quarter financial results before the markets opened on Tuesday. The pharma giant said that it had $1.30 in earnings per share (EPS) ...
Read Full Story »

What to Watch When Merck and Pfizer Report Early on Tuesday

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) are each scheduled to release their second-quarter financial results before the markets open on Tuesday. These are just a ...
Read Full Story »

Is This Lexicon Pharmaceuticals Panic Overblown?

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with the firm. This decision comes after Lexicon ...
Read Full Story »

What This Mylan-Pfizer Pharma Juggernaut Will Look Like

Mylan N.V. (NASDAQ: MYL) released its second-quarter financial results before the markets opened on Monday. The pharmaceutical giant also announced a major update to its business involving Pfizer Inc. (NYSE: ...
Read Full Story »

Short Sellers Up the Ante in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Is Acadia Pharma’s Schizophrenia Treatment Done For?

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares dropped on Tuesday after the firm announced results from its late-stage study for the treatment of adult schizophrenia patients with persistent inadequate response to ...
Read Full Story »

Why Johnson & Johnson Shareholders May Have to Ignore Earnings Looking Ahead

One company that has been a champion for investors has been Johnson & Johnson (NYSE: JNJ). The company has grown and grown over the years with sales of consumer products, ...
Read Full Story »

Tuesday’s Biggest Biotech Movers

Tuesday was a breakout day for a few biotech companies that saw solid gains. With the markets at all-time highs, these companies could help push things higher. 24/7 Wall St. ...
Read Full Story »